Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

Peter Wilhelmsen; Jens Kjær; Karen Louise Thomsen; Christoffer Tandrup Nielsen; Anders Kirch Dige; Maciej Bogdan Maniecki; Niels Heegaard; Henning Grønbæk; Jens Dahlerup; Aase Handberg

doi:10.3109/13813455.2013.808671

Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

Peter Wilhelmsen, Jens Kjær, Karen Louise Thomsen, Christoffer Tandrup Nielsen, Anders Kirch Dige, Maciej Bogdan Maniecki, Niels Heegaard, Henning Grønbæk, Jens Dahlerup, Aase Handberg

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

10 Citations (Scopus)

Abstract

Abstract Context: Inflammatory bowel disease (IBD) induces increased risk of thrombo-embolism. CD36 is involved in platelet activation, glucose metabolism and inflammation. Objective: The relationship between CD36 expression on platelets and monocytes, plasma sCD36, and CD36-positive platelet-derived microparticles (PDMPs) and inflammation in both active IBD and after one week of anti-tumour necrosis alpha antibody (anti-TNF) treatment was investigated. Material and methods: Patients with exacerbation of Crohn's disease (n = 8) or ulcerative colitis (n = 5) and 13 healthy controls were enrolled. Seven patients underwent anti-TNF treatment for one week. Platelet, monocyte, and PDMP-CD36 were measured by flow-cytometry. Results: Platelet CD36 expression was 34% higher in patients, and correlated with insulin resistance and fasting glucose. sCD36 was 37% lower and restored after anti-TNF treatment. Conclusion: Elevated platelet CD36 expression may contribute to increased risk of thrombo-embolism in active IBD. This may not entirely be attributed to inflammation and secondary insulin resistance may play a role.

Original language	English
Journal	Archives of Physiology and Biochemistry
Pages (from-to)	202-208
ISSN	1381-3455
DOIs	https://doi.org/10.3109/13813455.2013.808671
Publication status	Published - 17 Jul 2013

Access to Document

10.3109/13813455.2013.808671

Cite this

Wilhelmsen, P., Kjær, J., Thomsen, K. L., Nielsen, C. T., Dige, A. K., Maniecki, M. B., Heegaard, N., Grønbæk, H., Dahlerup, J., & Handberg, A. (2013). Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. Archives of Physiology and Biochemistry, 202-208. https://doi.org/10.3109/13813455.2013.808671

@article{371d4e57da0642bab86256a489bc29b2,

title = "Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease",

abstract = "Abstract Context: Inflammatory bowel disease (IBD) induces increased risk of thrombo-embolism. CD36 is involved in platelet activation, glucose metabolism and inflammation. Objective: The relationship between CD36 expression on platelets and monocytes, plasma sCD36, and CD36-positive platelet-derived microparticles (PDMPs) and inflammation in both active IBD and after one week of anti-tumour necrosis alpha antibody (anti-TNF) treatment was investigated. Material and methods: Patients with exacerbation of Crohn's disease (n = 8) or ulcerative colitis (n = 5) and 13 healthy controls were enrolled. Seven patients underwent anti-TNF treatment for one week. Platelet, monocyte, and PDMP-CD36 were measured by flow-cytometry. Results: Platelet CD36 expression was 34% higher in patients, and correlated with insulin resistance and fasting glucose. sCD36 was 37% lower and restored after anti-TNF treatment. Conclusion: Elevated platelet CD36 expression may contribute to increased risk of thrombo-embolism in active IBD. This may not entirely be attributed to inflammation and secondary insulin resistance may play a role.",

author = "Peter Wilhelmsen and Jens Kj{\ae}r and Thomsen, {Karen Louise} and Nielsen, {Christoffer Tandrup} and Dige, {Anders Kirch} and Maniecki, {Maciej Bogdan} and Niels Heegaard and Henning Gr{\o}nb{\ae}k and Jens Dahlerup and Aase Handberg",

year = "2013",

month = jul,

day = "17",

doi = "10.3109/13813455.2013.808671",

language = "English",

pages = "202--208",

journal = "Archives of Physiology and Biochemistry",

issn = "1381-3455",

publisher = "Taylor and Francis Ltd.",

}

Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. / Wilhelmsen, Peter; Kjær, Jens; Thomsen, Karen Louise et al.
In: Archives of Physiology and Biochemistry, 17.07.2013, p. 202-208.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

AU - Wilhelmsen, Peter

AU - Kjær, Jens

AU - Thomsen, Karen Louise

AU - Nielsen, Christoffer Tandrup

AU - Dige, Anders Kirch

AU - Maniecki, Maciej Bogdan

AU - Heegaard, Niels

AU - Grønbæk, Henning

AU - Dahlerup, Jens

AU - Handberg, Aase

PY - 2013/7/17

Y1 - 2013/7/17

N2 - Abstract Context: Inflammatory bowel disease (IBD) induces increased risk of thrombo-embolism. CD36 is involved in platelet activation, glucose metabolism and inflammation. Objective: The relationship between CD36 expression on platelets and monocytes, plasma sCD36, and CD36-positive platelet-derived microparticles (PDMPs) and inflammation in both active IBD and after one week of anti-tumour necrosis alpha antibody (anti-TNF) treatment was investigated. Material and methods: Patients with exacerbation of Crohn's disease (n = 8) or ulcerative colitis (n = 5) and 13 healthy controls were enrolled. Seven patients underwent anti-TNF treatment for one week. Platelet, monocyte, and PDMP-CD36 were measured by flow-cytometry. Results: Platelet CD36 expression was 34% higher in patients, and correlated with insulin resistance and fasting glucose. sCD36 was 37% lower and restored after anti-TNF treatment. Conclusion: Elevated platelet CD36 expression may contribute to increased risk of thrombo-embolism in active IBD. This may not entirely be attributed to inflammation and secondary insulin resistance may play a role.

AB - Abstract Context: Inflammatory bowel disease (IBD) induces increased risk of thrombo-embolism. CD36 is involved in platelet activation, glucose metabolism and inflammation. Objective: The relationship between CD36 expression on platelets and monocytes, plasma sCD36, and CD36-positive platelet-derived microparticles (PDMPs) and inflammation in both active IBD and after one week of anti-tumour necrosis alpha antibody (anti-TNF) treatment was investigated. Material and methods: Patients with exacerbation of Crohn's disease (n = 8) or ulcerative colitis (n = 5) and 13 healthy controls were enrolled. Seven patients underwent anti-TNF treatment for one week. Platelet, monocyte, and PDMP-CD36 were measured by flow-cytometry. Results: Platelet CD36 expression was 34% higher in patients, and correlated with insulin resistance and fasting glucose. sCD36 was 37% lower and restored after anti-TNF treatment. Conclusion: Elevated platelet CD36 expression may contribute to increased risk of thrombo-embolism in active IBD. This may not entirely be attributed to inflammation and secondary insulin resistance may play a role.

U2 - 10.3109/13813455.2013.808671

DO - 10.3109/13813455.2013.808671

M3 - Journal article

C2 - 23862574

SN - 1381-3455

SP - 202

EP - 208

JO - Archives of Physiology and Biochemistry

JF - Archives of Physiology and Biochemistry

ER -

Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

Abstract

Access to Document

Fingerprint

Cite this